INCIVEK
LOE ApproachingNDAORALTABLETPriority Review
Approved
May 2011
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INCIVEK is an oral small-molecule tablet approved by the FDA in May 2011 for an indication managed by Vertex Pharmaceuticals. The specific mechanism of action and indication are not disclosed in available data, but the product operates as a small-molecule therapeutic in tablet form.
LOE Approaching2.1 years to LOE
Product is in late-stage lifecycle with 2.1 years until loss of exclusivity, signaling potential team downsizing and transition focus for commercial functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Worked on INCIVEK at Vertex Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.